Success Metrics

Clinical Success Rate
90.0%

Based on 18 completed trials

Completion Rate
90%(18/20)
Active Trials
5(18%)
Results Posted
106%(19 trials)
Terminated
2(7%)

Phase Distribution

Ph phase_1
4
14%
Ph phase_2
2
7%
Ph phase_4
5
18%
Ph phase_3
11
39%
Ph early_phase_1
1
4%

Phase Distribution

5

Early Stage

2

Mid Stage

16

Late Stage

Phase Distribution23 total trials
Early Phase 1First-in-human
1(4.3%)
Phase 1Safety & dosage
4(17.4%)
Phase 2Efficacy & side effects
2(8.7%)
Phase 3Large-scale testing
11(47.8%)
Phase 4Post-market surveillance
5(21.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

18 of 20 finished

Non-Completion Rate

10.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

28

all time

Status Distribution
Active(6)
Completed(18)
Terminated(2)
Other(2)

Detailed Status

Completed18
Recruiting3
Active, not recruiting2
Terminated2
unknown2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
28
Active
5
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.3%)
Phase 14 (17.4%)
Phase 22 (8.7%)
Phase 311 (47.8%)
Phase 45 (21.7%)

Trials by Status

enrolling_by_invitation14%
active_not_recruiting27%
recruiting311%
terminated27%
completed1864%
unknown27%

Recent Activity

5 active trials
Showing 5 of 28
active_not_recruitingphase_3

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326
completedphase_4

Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia

NCT04158752
active_not_recruitingphase_3

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

NCT03432286
recruitingearly_phase_1

Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease

NCT07323927
enrolling_by_invitation

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View all 28 trials

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT04616326Phase 3

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Active Not Recruiting
NCT04158752Phase 4

Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia

Completed
NCT03432286Phase 3

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Active Not Recruiting
NCT07323927Early Phase 1

Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease

Recruiting
NCT06212661

Migraine Medication Effects on Urinary Symptoms

Enrolling By Invitation
NCT06085144

Emgality for Migraine in Breastmilk

Recruiting
NCT04628429

CGRP Inhibition, Autonomic Function, and Migraine

Recruiting
NCT05127486Phase 4

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Completed
NCT05284019Phase 4

Real World Effectiveness of Eptinezumab in Participants With Migraine

Terminated
NCT05492695Phase 4

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

Terminated
NCT03963232Phase 3

A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

Completed
NCT05281770

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

Unknown
NCT02614261Phase 3

Evaluation of Galcanezumab in the Prevention of Chronic Migraine

Completed
NCT04294147Phase 4

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

Completed
NCT02797951Phase 3

A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

Completed
NCT04085289Phase 1

A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants

Completed
NCT02959177Phase 2

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

Completed
NCT04803513

Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly

Unknown
NCT04179474Phase 1

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Completed
NCT02959190Phase 3

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine

Completed

Drug Details

Intervention Type
DRUG
Total Trials
28